A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforg...
Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal
This is an open-label, non-randomized trial that will be conducted at three clinical sites, Thomas Jefferson University (TJU), the Hospital of the University of Pennsylvania (HUP) and University of Be...
Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide
Postpartum prophylactic HCTZ administration for prevention and relapse of preeclampsia or gestational hypertension....
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or ov...
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweig...
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hy...
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study...
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12)....
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the...
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subje...
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
Researchers are looking for other ways to treat pulmonary arterial hypertension (PAH). Sotatercept is a study medicine that is designed to treat PAH. A past study, MK-7962-024 (LIGHTRAY) (NCT06664801...
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
Researchers are looking for new ways to treat people with a type of pulmonary hypertension called combined postcapillary and precapillary pulmonary hypertension (Cpc-PH). This study focuses on Cpc-PH ...
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), deriv...
A Study of Mosliciguat in PH-ILD
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension asso...
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosen...
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participant...
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
The purpose of the study is to learn how the study medicine called PF-07868489 is tolerated and acts in healthy adult people and people with pulmonary arterial hypertension (PAH). Part A: An investi...
Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
Randomized, triple-masked, parallel arm clinical trial of empagliflozin versus placebo in pulmonary arterial hypertension (PAH) participants on stable approved PAH-targeted medical therapy....
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to \<18 years of age with PAH World ...
A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension
The primary purpose of the study is to assess the effect of lorundrostat taken orally (po) once a day on the Apnea-Hypopnea Index (AHI) in participants with moderate to severe obstructive sleep apnea ...
Metformin for Pulmonary Hypertension HFpEF
The main objective of this study is to determine the clinical efficacy of metformin versus placebo and the therapeutic response with regards to functional capacity and hemodynamics in PH-HFpEF....
Top Cities for Hypertension Clinical Trials
Hypertension clinical trials are recruiting across 100 cities. Here are the cities with the most active studies:
About Hypertension
Hypertension, or high blood pressure, is a common condition that increases the risk of heart disease, stroke, and kidney damage. Often called the "silent killer" because it usually has no symptoms. Management includes lifestyle modifications and medications to lower blood pressure.
Clinical trials are advancing new treatments for hypertension. Currently, 21 studies are recruiting a combined 5,434 participants across the United States. Research is being conducted by 17 organizations including Eli Lilly and Company, Thomas Jefferson University, The University of Texas Medical Branch, Galveston and 14 others.
2026 Hypertension Research Landscape
As of March 2026, the hypertension clinical trial landscape includes 21 actively recruiting studies across 100 cities in the United States. These studies are collectively seeking 5,434 participants, with an average enrollment target of 259 per study.
Research is being led by 17 different organizations, including Eli Lilly and Company, Thomas Jefferson University, The University of Texas Medical Branch, Galveston, Novartis Pharmaceuticals, GB002, Inc., and 12 others. The large number of sponsors reflects significant research interest and investment in hypertension treatment advancement.
Geographically, hypertension trials are most concentrated in Los Angeles, California (6 trials); San Francisco, California (6 trials); Phoenix, Arizona (5 trials); Jacksonville, Florida (5 trials); Sacramento, California (5 trials) and 7 other cities.
Featured Hypertension Studies
Highlighted recruiting studies for hypertension, selected by enrollment size and research scope.
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.
Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal
This is an open-label, non-randomized trial that will be conducted at three clinical sites, Thomas Jefferson University (TJU), the Hospital of the University of Pennsylvania (HUP) and University of Bern (UB). Enrollment will be allocated into one of 4 different cohorts depending on the inclusion criteria for each cohort. Cohort 1: Patients scheduled for hepatic vein pressure gradient (HVPG) meas...
Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide
Postpartum prophylactic HCTZ administration for prevention and relapse of preeclampsia or gestational hypertension.
Frequently Asked Questions About Hypertension Clinical Trials
Are there hypertension clinical trials near me?
Yes, there are 21 hypertension clinical trials currently recruiting across 100+ cities in the United States, including Los Angeles, California; San Francisco, California; Phoenix, Arizona. Browse the studies above to find one at a location convenient for you.
How do I join a hypertension clinical trial?
To join a hypertension clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are hypertension clinical trials free?
Yes, participation in hypertension clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of hypertension treatments are being studied?
Current hypertension clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 17 research organizations.
Is it safe to participate in hypertension clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov